Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
David Epstein
|
| gptkbp:focusesOn |
oncology
|
| gptkbp:formerName |
gptkb:Seattle_Genetics
|
| gptkbp:founded |
1997
|
| gptkbp:founder |
gptkb:Clay_Siegall
|
| gptkbp:headquartersLocation |
gptkb:Bothell,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Seagen
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Adcetris
gptkb:Padcev gptkb:Tivdak gptkb:Tukysa |
| gptkbp:numberOfEmployees |
approximately 3000
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:specializesIn |
antibody-drug conjugates
|
| gptkbp:stockSymbol |
gptkb:SGEN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.seagen.com/
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:bfsLayer |
4
|